Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abacus Global Management, Inc. (“Abacus” or “the Company”) (NASDAQ: ABL). Investors who purchased Abacus securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Abacus has violated federal securities laws.

Investigation Details

Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: “Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die.” According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have “red flags” in their past.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Abacus securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660